Flatiron welds deal with Lifebit to leverage AI in tracking cancer data

Flatiron Health has inked a multiyear deal with Lifebit, which uses AI to collect biomedical data to advance research and development of treatments targeting cancer.

The collaboration will use Lifebit’s technology platform to collect data from hospitals, healthcare providers, research organizations and clinical trials that can then be used in drug development and improved patient care, the companies said in a May 31 press release. Financial terms of the deal weren’t disclosed.

“The advanced capabilities of Lifebit’s Trusted Research Environment, coupled with our focus to reimagine the infrastructure of cancer care, will enable us to unlock the potential of cancer data to support research into new therapies and help get them to patients more quickly,” Arun Sujenthiran, M.D., Flatiron’s U.K. clinical lead and senior medical director, said in the release.

Lifebit’s platform is currently being used to support research initiatives by Genomics England, the Danish National Genome Center and NIHR Cambridge Biomedical Research Center. It allows researchers and clinicians to securely analyze data at its point of origin while connecting other data sets without the data being moved or copied. 

In early May, Flatiron entered a partnership with Sanofi to retool clinical trials focused on cancer treatments by leveraging more efficient transfers of data.